Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company leveraging biomarkers and augmented intelligence (AI) to help physicians identify the source of chronic low back pain, announced the appointment of Daniel Keefe as Commercial Director, Western U.S. The move is intended to build on Aclarion's existing footprint in the region and support the continued adoption of its Nociscan platform, which has seen triple-digit growth in utilization.
Keefe brings more than 20 years of experience in medical device and healthcare technology sales, having held leadership roles at Centinel Spine, Brainlab, Zimmer Biomet, and Intuitive Surgical. Most recently, he served as Regional Sales Manager at Centinel Spine, where he consistently exceeded performance targets and delivered significant year-over-year growth across Northern California. His expertise includes building strategic relationships with surgeons and hospital leadership, launching new technologies, and expanding market presence in competitive environments across spine, orthopedics, and image-guided surgery.
"Dan brings a proven track record of driving commercial growth and expanding adoption of innovative surgical technologies," said Brent Ness, Chief Executive Officer of Aclarion. "His deep experience working with spine surgeons and hospital systems, combined with his ability to build and scale high-performing territories, will be instrumental as we continue to grow our presence in the Western U.S. and support broader clinical use of Nociscan."
Chronic low back pain affects an estimated 266 million people worldwide, making it one of the most pervasive health challenges. Aclarion's Nociscan is the first evidence-supported, cloud-based platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. The platform objectively quantifies chemical biomarkers associated with disc pain using proprietary signal processing techniques and AI algorithms. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, and the company reports a 97% surgical success rate when all Nociscan-positive discs are treated.
"I'm excited to join Aclarion at a time when Nociscan is gaining meaningful traction across the clinical community," said Daniel Keefe, Commercial Director, Western U.S. "The ability to provide physicians with objective insight into the source of pain represents a significant advancement in how chronic low back pain is evaluated. I look forward to working with physicians and spine centers across the Western U.S. to expand access to Nociscan and support its continued integration into clinical practice."
To find a Nociscan center, view the company's site map here. For more information on Nociscan, visit www.aclarion.com. The latest news and updates relating to $ACON are available in the company's newsroom at https://tinyurl.com/aconnewsroom.
